Workshop Summary: Introduction to Rational Design of New Means for Therapeutic Modulation of Function of the TNF Family

Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 691)


The conference session entitled “Rational Design of New Means for Therapeutic Modulation of Function of the TNF Family,” as the title implies, explored multiple novel strategies to develop new drugs acting as agonists and antagonists of the TNF–TNFR superfamily for treatment of cancer and chronic or acute inflammatory diseases, respectively. The approved clinical use of agonistic superfamily ligands in cancer therapy is presently restricted to TNF itself, used in a few selected indications that allow locoregional application (e.g., isolated limb perfusion).


Isolate Limb Perfusion Acute Inflammatory Disease TNFR2 Receptor Trail Death Receptor TNFR Superfamily 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    (2008) Top 20 Biologics - 2008 Sales of Antibodies & Proteins. In R&D Pipeline News, La Merie Business Intelligence (article dated March 9, 2009, available at
  2. 2.
    Kaymakcalan Z et al (2009) Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 131 (2):308–316CrossRefPubMedGoogle Scholar
  3. 3.
    Mukai Y et al (2009) Fast binding kinetics and conserved 3D structure underlie the antagonistic activity of mutant TNF: useful information for designing artificial proteo-antagonists. J Biochem 146 (2):167–172CrossRefPubMedGoogle Scholar
  4. 4.
    McAlpine FE et al (2009) Inhibition of soluble TNF signaling in a mouse model of Alzheimer’s disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis 34 (1):163–177CrossRefPubMedGoogle Scholar
  5. 5.
    Olleros ML et al (2009) Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette-Guérin(BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis. J Inf Dis 199 (7):1109–1120Google Scholar
  6. 6.
    Zalevsky J et al (2007) Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 179 (3):1872–1883PubMedGoogle Scholar
  7. 7.
    Driggers EM et al (2008) The exploration of macrocycles for drug discovery--an underexploited structural class. Nat Rev Drug Discov 7 (7):608–624CrossRefPubMedGoogle Scholar
  8. 8.
    Wu J et al (2009) Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-α production in human whole blood. Bioorg Med Chem Lett 19 (13):3485–3488CrossRefPubMedGoogle Scholar
  9. 9.
    Tansey MG, Szymkowski DE (2009) The TNF superfamily in 2009: new pathways, new indications and new drugs. Drug Discov Today 14(23–24):1082–1088CrossRefPubMedGoogle Scholar
  10. 10.
    Schwarz EM, Ritchlin CT (2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther 9 Suppl 1, S7CrossRefPubMedGoogle Scholar
  11. 11.
    Razmara M et al (2009) Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis. Am J Pathol 174 (2):460–474CrossRefPubMedGoogle Scholar
  12. 12.
    Gerspach J et al (2009) Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. Biofactors 35 (4):364–372CrossRefPubMedGoogle Scholar
  13. 13.
    Gerspach J et al (2009) Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results Probl Cell Differ 49:241–273CrossRefPubMedGoogle Scholar
  14. 14.
    Duiker EW et al (2009) Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res 15 (6):2048–2057CrossRefPubMedGoogle Scholar
  15. 15.
    Labrinidis A et al (2009) Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin Cancer Res 15 (6):1998–2009CrossRefPubMedGoogle Scholar
  16. 16.
    Chiang EY et al (2009) Targeted depletion of lymphotoxin-α-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 15 (7):766–773CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Institute of Cell Biology and Immunology, University of StuttgartStuttgartGermany
  2. 2.Biotherapeutics Xencor, Inc.MonroviaUSA

Personalised recommendations